Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew L Mellor

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Current Opinion in Oncology|December 6, 2013
Metabolic control of tumour progression and antitumour immunityLei Huang, Andrew L Mellor
Current Pharmaceutical Design|February 7, 2003
Macrophages and the regulation of self-reactive T cellsDavid H Munn, Andrew L Mellor
Handbook of Experimental Pharmacology|November 26, 2008
T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenaseDavid J Kahler, Andrew L Mellor
Immunological Reviews|September 16, 2006
The tumor-draining lymph node as an immune-privileged siteDavid H Munn, Andrew L Mellor
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2011
Physiologic control of the functional status of Foxp3+ regulatory T cellsAndrew L Mellor, David H Munn
The Journal of Clinical Investigation|May 4, 2007
Indoleamine 2,3-dioxygenase and tumor-induced toleranceDavid H Munn, Andrew L Mellor
Nature Reviews. Immunology|October 2, 2004
IDO expression by dendritic cells: tolerance and tryptophan catabolismAndrew L Mellor, David H Munn
Trends in Immunology|October 30, 2012
Indoleamine 2,3 dioxygenase and metabolic control of immune responsesDavid H Munn, Andrew L Mellor
Nature Reviews. Immunology|December 8, 2007
Creating immune privilege: active local suppression that benefits friends, but protects foesAndrew L Mellor, David H Munn
Trends in Immunology|February 4, 2016
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and ToleranceDavid H Munn, Andrew L Mellor
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Current Opinion in Oncology|December 6, 2013
Metabolic control of tumour progression and antitumour immunityLei Huang, Andrew L Mellor
Current Pharmaceutical Design|February 7, 2003
Macrophages and the regulation of self-reactive T cellsDavid H Munn, Andrew L Mellor
Handbook of Experimental Pharmacology|November 26, 2008
T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenaseDavid J Kahler, Andrew L Mellor
Immunological Reviews|September 16, 2006
The tumor-draining lymph node as an immune-privileged siteDavid H Munn, Andrew L Mellor
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2011
Physiologic control of the functional status of Foxp3+ regulatory T cellsAndrew L Mellor, David H Munn
The Journal of Clinical Investigation|May 4, 2007
Indoleamine 2,3-dioxygenase and tumor-induced toleranceDavid H Munn, Andrew L Mellor
Nature Reviews. Immunology|October 2, 2004
IDO expression by dendritic cells: tolerance and tryptophan catabolismAndrew L Mellor, David H Munn
Trends in Immunology|October 30, 2012
Indoleamine 2,3 dioxygenase and metabolic control of immune responsesDavid H Munn, Andrew L Mellor
Nature Reviews. Immunology|December 8, 2007
Creating immune privilege: active local suppression that benefits friends, but protects foesAndrew L Mellor, David H Munn
Trends in Immunology|February 4, 2016
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and ToleranceDavid H Munn, Andrew L Mellor
Pageof 11